The Zacks Analyst Blog Highlights: Alphabet, GlaxoSmithKline, T-Mobile, Northrop Grumman And CSX

For Immediate Release

Chicago, IL – July 24, 2017 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Alphabet (NASDAQ:GOOGL) (NASDAQ: GOOGL – Free Report), GlaxoSmithKline (NYSE: GSK – Free Report), T-Mobile (NASDAQ: TMUS – Free Report), Northrop Grumman (NYSE: NOC – Free Report) and CSX Corp (NASDAQ: CSX – Free Report).

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.

Here are highlights from Friday’s Analyst Blog:

Top Stock Reports for Alphabet, GlaxoSmithKline and T-Mobile

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Alphabet (NASDAQ: GOOGL – Free Report), GlaxoSmithKline (NYSE: GSK – Free Report) and T-Mobile (NASDAQ: TMUS – Free Report). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today. You can see all of today’s research reports here >>>

Buy-rated Alphabet shares have outperformed the Zacks Internet-Services over the last one year period (the stock is up +30.6% vs. +22.1% gain for the sector) on the back of innovation and strategic acquisitions, while Android OS should continue to generate strong cash flows. Its diversification strategy is also positive, but requires significant investment and involves uncertain payback periods, particularly since these efforts are at the cutting edge of technology.

Alphabet has shown good execution to date, more or less maintaining its dominant share in a competitive, fast-growing search market. (You can read the full research report on Alphabet here >>> ).

Shares of GlaxoSmithKline have gained more +11% year-to-date, marginally underperforming the Zacks Large-Cap Pharmaceuticals industry, which has gained +13.2% over the same period. However, Glaxo should continue to see strong performances from all of its business segments – Pharmaceuticals, Vaccines and Consumer Healthcare.

The Zacks analyst likes Glaxo’s efforts to develop its pipeline as well. Performance of new products as well as of those acquired from Novartis has been encouraging. However, persistent challenges like stiff competition, genericization and pricing pressure along with slowing growth in emerging markets have been affecting the company’s performance. In particular, pricing dynamics and competitive pressure are hurting sales of its top-selling drug Advair.

Meanwhile, Advair is expected to face generic competition in the U.S. soon which will further hurt sales. However, estimates have risen ahead of Glaxo’s Q2 earnings release. The company has also recorded a string of positive earnings surprises in recent quarters. (You can read the full research report on GlaxoSmithKline here >>> ).

T-Mobile ’s shares have been strong performers lately - the stock is up +34.5% over the last 12 months, handily outperforming the Zacks National Wireless industry (down -12%) and the broader Zacks Telecommunications Services industry (down -6.8%). T-Mobile US posted impressive second-quarter 2017 financial results.

The Zacks analyst thinks T-Mobile US' network expansion plans of 5G trials with Ericsson (BS:ERICAs) and Nokia (HE:NOKIA), 4G LTE network improvement and expansion, deployment of LTE-U technology and unlimited ‘T-Mobile One’ plan have driven additional net customers of 1.333 million. The company raised its outlook for 2017 on the back of huge subscriber gains.

However, competitive and saturated wireless market and marketing costs of the low-priced promotional plans are major headwinds. Also, it faces increased scrutiny in its working conditions, lawsuits and fines by regulatory authorities. (You can read the full research report on T-Mobile here >>> ).

Other noteworthy reports we are featuring today include Northrop Grumman (NYSE: NOC – Free Report ) and CSX Corp (NASDAQ: CSX – Free Report).

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Strong Stocks that Should Be in the News

Many are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has nearly tripled the market from 1988 through 2015. Its average gain has been a stellar +26% per year. See these high-potential stocks free >>.

Get the full Report on GOOGL - FREE

Get the full Report on GSK – FREE

Get the full Report on TMUS - FREE

Get the full Report on NOC - FREE

Get the full Report on CSX - FREE

Follow us on Twitter: https://twitter.com/zacksresearch

Join us on Facebook (NASDAQ:FB): https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339

support@zacks.com

https://www.zacks.com/

This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.